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BIOMATERIAL SINTETIK: KAJIAN GENOTOKSISITI KE ATAS 
POLIHIDROKSIBUTIRAT
ABSTRAK
Tujuan kajian ini adalah untuk memastikan genoketoksisti ke atas  
polihidroksibutirat (PHB) yang dihasilkan dalam bentuk fiber pendek dan padu dan 
dikeluarkan oleh Pusat Pengajian Sains Biologi, Universiti Sains Malaysia, Pulau Pinang, 
Malaysia, dengan menggunakan 3 jenis ujian yang berbeza: Ujian Kemutagenan 
Salmonella (ujian Ames), Ujian In Vitro kromosomal keaberanan mamalia dan analisis 
pernyataan gen.
PHB telah diuji pada kepekatan yang berbeza-beza (0.3125, 0.625, 1.25, 2.5 dan 5 
mg/ml) dalam ketiga-tiga ujian. Untuk ujian Ames, PHB telah dieram dengan varian 
genotip khusus bakteria, Salmonella typhimurium, yang membawa mutasi dalam beberapa 
gen. Lima penguji strain (TA1535, TA1537, TA1538, TA98 dan TA100) telah digunakan, 
dengan dan tanpa menggunakan campuran sistem pengaktifan metabolik S9 dan ujian ini 
telah dinilai berdasarkan kepada jumlah koloni revertant. Pada masa yang sama, kawalan 
positif atau negatif. Serentak, kawalan negatif ujian dengang menggunakan air suling yang 
steril dan kawalan positif ujian dengang menggunakan 9-aminoacridine hydrochloride 
monohydrate (98%) and 4-Nitro-O-phenylenediamine (98%) tanpa menggunakan 
campuran sistem pengaktifan metabolik S9 dan 2-aminoanthracene dengan S9 telah 
membawa keluar. Untuk menilai keaberanan kromosom, garis sel osteoblas manusia 
(HOS, CRL-1543) dari jenis sel kultur Amerika telah didedahkan kepada PHB, air suling 
yang steril (kawalan negatif) dan Mitomisin (kawalan positif), dengan dan tanpa 
menggunakan campuran sistem pengaktifan metabolik S9. Untuk mengkaji analisis 
pernyataan gen, garis sel fibroblas MRC-5 telah dirawat dengan PHB pada kepekatan 
yang berbeza dan dieram untuk 1, 12, 24 dan 48 jam secara berasingan untuk setiap 
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kepekatan. Jumlah RNA diasingkan dan dianalisa untuk pernyataan gen-gen p53, c-myc, 
bcl-xl dan bcl-xs.
Keputusan ujian Ames menunjukkan bahawa jumlah purata koloni-koloni revertant 
per plat yang dirawat dengan PHB (min koloni-koloni revertant adalah dalam lingkungan 
28 hingga 344 koloni/plat tanpa S9 dan dari 150 hingga 499 koloni/plat dengan S9) adalah 
kurang dari sekali ganda jika dibandingkan dengan yang kawalan negatif (147 hingga 346 
koloni/plat tanpa S9 dan 340 hingga 443 koloni/plat dengan S9). Ketiadaan penambahan 
bilangan koloni-koloni secara sekurang-kurangnya sekali ganda dengan bahan ujian 
menandakan yang PHB adalah tidak mutagenan.Untuk ujian keaberanan kromosom, tidak 
terdapat petunjuk sebarang mutagenan disebabkan oleh PHB pada garis sel HOS seperti 
yang ditunjukkan oleh nilai indeks mitotik (min indeks-indeks mitotik adalah dalam 
lingkungan 3.55(0.06) hingga 4.95 (0.77) peratus tanpa S9 dan dari 3.10 (0.14) hingga 
5.20 (0.98) peratus dengan S9) juga tidak terdapat keaberanan kromosom. Ini 
menunjukkan yang PHB adalah tidak sitotoksik dan tidak menghasilkan keaberanan 
kromosom pada garis sel HOS. Dalam analisis pernyataan gen, garis sel fibroblas (MRC-
5) yang dirawat dengan PHB pada kepekatan yang berbeza dan pada tempoh masa 
berbeza menunjukkan peningkatan di atas atau di bawah penyataan penurunan pada gen-
gen p53 (kedekut IDV banjaran dari 36100 hingga 36295), c-myc (kedekut IDV banjaran 
dari 33110 hingga 33270), bcl-xl (kedekut IDV banjaran dari  31230 hingga 31443) dan 
bcl-xs (kedekut IDV banjaran dari 33103 hingga 33290) jika dibandingkan dengan yang 
kawalan negatif (kedekut IDV banjaran dari 31230 hingga 36240).
Ujian-ujian yang berbeza yang dijalankan dalam kajian ini menunjukkan bahawa 
PHB (yang dihasilkan oleh Pusat Pengajian Sains Biologi, Universiti Sains Malaysia, Pulau 
Pinang, Malaysia) adalah tidak genotoksik dalam keadaan ujian sekarang.
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A STUDY OF THE GENOTOXICITY OF POLYHYDROXYBUTYRATE:
A SYNTHETIC BIOMATERIAL
ABSTRACT
The purpose of this study is to determine the genotoxicity of polyhydroxybutyrate 
(PHB), produced in short solid fibre form and manufactured by School of Biological 
Sciences, Universiti Sains Malaysia, Penang, Malaysia, using three different tests: The 
Salmonella mutagenicity test (Ames test), in vitro mammalian chromosomal aberration test
and gene expression analysis. 
PHB was tested at various concentrations (0.3125, 0.625, 1.25, 2.5 and 5 mg/ml) in 
all the three tests. For the Ames test, PHB was incubated with special genotype variants of 
the bacterium Salmonella typhimurium, which carry mutations in several genes. Five tester 
strains (TA1535, TA1537, TA1538, TA98 and TA100) were used, both with and without 
metabolic activation system S9 mix and the test was assessed based on the number of 
revertant colonies. Simultaneously, negative control tests using sterile distilled water and 
positive control tests using sodium azide, 9-aminoacridine hydrochloride monohydrate 
(98%) and 4-Nitro-O-phenylenediamine (98%) without metabolic activation system (S9) 
and 2-aminoanthracene with metabolic activation system (S9) were carried out. To assess 
the chromosomal aberrations, human osteoblast cell lines (HOS, CRL-1543) from 
American type cell culture were exposed to PHB, sterile distilled water (Negative control) 
and Mitomycin C (Positive control), both with and without metabolic activation system S9 
mix. For the gene expression analysis, the fibroblast cell lines MRC-5 were treated with 
PHB and incubated for 1, 12, 24 and 48 hours separately for each concentration. Total 
RNA was isolated and analysed for the expression of p53, c-myc, bcl-xl and bcl-xs genes.
The results of Ames test showed that the average number of revertant colonies per 
plate treated with PHB (28 to 344 colonies/plate without S9 and 150 to 499 colonies/plate 
xxiv
with S9) was less than double as compared to that of negative control (147 to 346 
colonies/plate without S9 and 340 to 443 colonies/plate with S9). The absences of 
increase in the number of revertant colonies by at least double with the test material 
indicate that PHB was non-mutagenic. In the case of chromosome aberration test, there 
was no indication of any mutagenicity due to PHB on the HOS cell line as revealed by the 
mitotic index values [3.55(0.06) to 4.95(0.77) per cent without S9 and 3.10(0.14) to 
5.20(0.98) per cent with S9]. Also, no chromosome aberrations were observed in the HOS 
cell lines treated with PHB. The results of gene expression analysis carried out on 
fibroblast cell line (MRC-5) treated with PHB at different timings did not show over or under 
expression of the genes, p53 (Mean IDV range from 36100 to 36295), c-myc (Mean IDV 
range from 33110 to 33270), bcl-xl (Mean IDV range from 31230 to 31443) and bcl-xs 
(Mean IDV range from 33103 to 33290) as compared to that of negative controls (Mean 
IDV range from 31230 to 36240).
Hence, the present study indicates that PHB produced by School of Biological 
Sciences, Universiti Sains Malaysia, Penang, Malaysia is non-genotoxic under the present 
test conditions.
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Biomaterials 
A biomaterial is a non-viable material used in medical devices intended to 
interact with biological systems (Williams, 1987). They may be distinguished from other 
materials in that they possess a combination of properties, including chemical, 
mechanical, physical and biological properties that render them suitable for safe, 
effective and reliable use within a physiological environment. Biomaterial is a term 
used to indicate materials that constitute parts of medical implants, extracorporeal 
devices and disposables that have been utilized in medicine, surgery, dentistry and 
veterinary medicine as well as in every aspect of patient health care. The National 
Institutes of Health Consensus Development Conference defined biomaterial as ‘‘any 
substance (other than a drug) or combination of substances, synthetic or natural in 
origin, which can be used for any period of time, as a whole or as a part of a system 
which treats, augments or replaces any tissue, organ or function of the body’’ (Boretos 
and Eden, 1984).  
Biomaterials can be naturally or semi synthetically produced. Numerous natural 
and semi synthetic materials are available in the form of xenografts (from a different 
species), allografts (from the same species) or autografts (from the same organisms) 
and function well in facial, plastic and reconstructive surgery. Any synthetic biomaterial 
can also be referred to as an alloplasts.  There are a wide variety of alloplasts, most of 
which are specifically designed for either soft tissue or skeletal applications (Costantino 
et al., 1993). 
When a synthetic material is placed within the human body, tissue reacts 
towards the implant in a variety of ways depending on the material type. The 
mechanism of tissue interaction depends on the tissue response to the implant 
surface. Biomedical materials can be divided roughly into three main types which 
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governed by the tissue response. In broad terms, inert (more strictly, nearly inert) 
materials which elicit no or minimal tissue response. Active materials that encourage 
bonding to surrounding tissue with, for example, new bone growth being stimulated. 
Degradable or resorbable materials which are incorporated into the surrounding tissue, 
or may even, dissolve completely over a period of time. Metals are typically inert, 
ceramics may be inert, active or resorbable and polymers may be inert or resorbable 
(Czernuszka, 1996). 
1.2  Polyhydroxybutyrate 
Polyhydroxybutyrate (PHB) was the first polyhydroxyalkanoates (PHAs) to be 
discovered and was also the most widely studied and best characterized PHA.  PHA is 
polyesters of various hydroxyalkanoates that are synthesized by many gram-positive 
and gram-negative bacteria from at least 75 different genera. These polymers are 
accumulated intracellularly to levels as high as 90% of the cell dry weight under 
conditions of nutrient stress and act as a carbon and energy reserve (Madison and 
Huisman, 1999). 
PHB is accumulated as a membrane enclosed inclusion in many bacteria at up 
to 80% of the dry cell weight and has mechanical properties very similar to 
conventional plastics.  PHB was discovered by Lemoigne in the bacterium Bacillus 
megaterium in 1926. In subsequent years, it was also found in other species of 
bacteria, where it acts as a source of carbon and energy. PHB is a non-toxic, insoluble 
in water thermoplastic displaying chemical and physical properties similar to 
polypropylene. PHB is used as a biodegradable, ecologically friendly alternative to 
conventional plastics (i.e. polypropylene) matrix component of composites reinforced 
particularly with fibres of natural origin (Peijs, 2002).  
  A large number of review papers are available, which give a detailed 
description about the general features of PHAs (Byrom, 1987; Brandl et al., 1990; 
Steinbuchel, 1991), characterization of PHA polymers (Brandl et al., 1990; Bonthrone 
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et al., 1992) and their biodegradation (Steinbuchel, 1991; Mergaert et al., 1992). 
However, there are no recent reviews which explain the genotoxicity of PHB. 
The bacteria that produce PHB can be divided into two groups. The first one 
includes Ralstonia eutropha (Alcaligenes eutropha) and consists of bacteria that 
produce short-chain PHA with C3–C5 monomers, while the second, which contains for 
example, Pseudomonas oleovorans, involves microorganisms that produce medium-
chain PHA with C6–C14 monomers (Anderson and Dawes, 1990; Steinbuchel, 1991; 
Poirier et al., 1995). 
Several papers appeared on PHB synthesis in transgenic plants (Nawrath et 
al., 1994; Poirier et al., 1995; Bohmert et al., 2000). All of them have been pointed to 
cause the accumulation of PHB in various plant organs with the expectation that the 
crops will produce the polymer for industrial use. The best result was obtained with 
Arabidopsis thaliana plants where PHB content was enhanced up to 42 mg/g (Bohmert 
et al., 2000); however the growth of the plants was markedly reduced. 
PHB has found more interesting applications as an implant material due to its 
biocompatibility and resorbability (Miller and Williams, 1987; Boeree et al., 1993). PHB 
was appeared ideal for use as temporary stents, bone plates, patches, nails and 
screws (Malm et al., 1992; Peng et al., 1996), though in some cases, its brittle 
mechanical properties limit its use.  
1.3 Biocompatibility and genotoxicity 
Biocompatibility denotes acceptance of the implant to the tissue surface. The 
toxicological properties of new substances must be examined in the form in which they 
are introduced into the market i.e. normally with considerable amounts of impurities. 
On the basis of the results obtained, the substances are classified and labelled in 
respect of their dangerous properties (Broschinski et al., 1998). Biocompatibility may 
generally be regarded as the ability of a material to interact with living cells/tissues or a 
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living system by not being toxic, injurious or causing immunological reactions while 
performing or functioning appropriately (Joel et al., 2004). 
Genotoxicity is the study of chemicals which can damage the genetic structure of 
living organisms (including humans) and thus cause problems such as mutations, 
cancer and birth defects. The primary function of genotoxicity testing is to investigate, 
using test cells or organisms, the potential of products to induce mutations in man that 
may be transmitted via the germ cells to future generations. Scientific data generally 
support the hypotheses that DNA damage in somatic cells is a critical event in the 
initiation of cancer. Such damage can result in mutations and tests to detect mutagenic 
activity may also identify chemicals that have the potential to lead to carcinogenesis. 
Thus, some of the tests are useful for the investigation of putative carcinogenic activity 
(ISO 10993 -3, 1998). 
   Based on the recommendations of the International Standard Organization (ISO 
10993-3, 1992) and the American Society for Testing and Materials (ASTM, 1987), 
therefore, three different representative test methods for the determination of genotoxic 
and mutagenic effects of the synthetic implant material PHB are applied: The 
Salmonella mutagenicity test (Ames test), in vitro mammalian chromosomal aberration 
test and gene expression analyses. 
1.4 The Salmonella mutagenicity test (Ames test) 
Testing of chemicals for mutagenicity in Salmonella typhimurium is based on 
the knowledge that a substance which is mutagenic in the bacterium is likely to be a 
carcinogen in laboratory animals and thus, by extension, present a risk of cancer to 
humans. The ease, rapidity and low cost of the test make it an important tool for 
screening substances for potential carcinogenicity. Several strains of the Salmonella 
typhimurium bacterium may be used for testing. Each is genetically different and hence 
using several strains in a test increases the opportunity of detecting a mutagenic 
chemical. All strains of Salmonella typhimurium used for mutagenicity testing carry a 
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defective (mutant) gene that prevents them from synthesizing the essential amino acid 
histidine from the ingredients in standard bacterial culture medium. Therefore, these 
"tester" strains can only survive and grow on medium that contains excess histidine. 
However, in the presence of a mutagenic chemical, the defective histidine gene may 
be mutated back to the functional state, allowing the bacterium to grow on standard 
medium that does not contain supplemental histidine (Mortelmans and Zeiger, 2000). 
Many chemicals are not mutagenic (or carcinogenic) in their native forms, but 
they are converted into mutagenic substances by metabolism in the liver. Since the 
Salmonella bacterium does not have the same metabolic capabilities as mammals, 
some test protocols utilize extracts of rat or hamster liver enzymes (S9) to promote 
metabolic conversion of the test chemical. This permits the investigator to determine if 
a chemical must be metabolized to express mutagenic activity. Some mutagenic 
chemicals are active with and without metabolism, while others are active only under 
one condition or the other (Malling, 1971; Ames et al., 1973b). 
Several doses (at least 5) of the test chemical and multiple strains of 
Salmonella typhimurium are used in each experiment. In addition, cultures are set up 
with and without added S9 at varying concentrations and a variety of culture conditions 
are employed to maximize the opportunity to detect a mutagenic chemical (Waleh et 
al., 1982). In analyzing data, the pattern and the strength of the mutant response are 
taken into account in determining the mutagenicity of a chemical. All observed 
responses are verified in repeat tests. If  there is no increase in mutant colonies is 
seen after testing several strains under several different culture conditions, the test 
chemical is considered to be non-mutagenic in the Salmonella test (Katzer et al., 
2003). 
1.5 In vitro mammalian chromosomal aberration test 
Chromosomal mutations and related events are the cause of many human 
genetic diseases and there is substantial evidence that chromosomal mutations and 
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related events causing alterations in oncogenes and tumors suppressor genes of 
somatic cells are involved in cancer induction in humans and experimental animals 
(Ishidate and Sofuni, 1985). 
The purpose of the in vitro chromosomal aberration test is to identify agents 
that caused structural chromosome aberrations in cultured mammalian cells (Evans, 
1976; Galloway et al., 1987). Structural aberrations may be of two types, chromosome 
or chromatid. With the majority of chemical mutagens, induced aberrations are of the 
chromatid type, but chromosome type aberrations also occur (Hilliard et al., 1998).  
This test is used to screen for possible mammalian mutagens and carcinogens. 
Many compounds that are positive in this test are mammalian carcinogens. The 
chromosome aberration test using cultured mammalian cells is one of the sensitive 
methods to predict environmental mutagens and/or carcinogens and is also a 
complementary test to the Salmonella / microsome assay (Ames test) (Ishidate et al., 
1998). 
Several short-term mutagenicity assays are being widely used for screening 
chemicals for carcinogenic potential. Gene mutations and chromosome aberrations, 
major endpoints for the evaluation of mutagenicity, are intimately involved in the initial 
and subsequent steps of carcinogenesis, oncogenes being commonly activated by 
gene mutations or chromosome aberrations in various types of cancers (Land et al., 
1983). Moreover, some mutagens are reported to cause chromosome aberrations 
alone, whereas, others solely induce gene mutations (Zeiger et al., 1990). 
1.6 Gene expression analyses  
In each and every organism, different genes are expressed in different cell and 
tissue types (spatial differences) and at different developmental stages (temporal 
differences). Analyses of these variations in gene expression will lead to a better 
understanding of disease states, targetting of drugs to specific cells, tissues or 
individual’s development of agricultural products (Narayanan,  2001). 
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Studies of gene expression changes induced by genotoxins have focussed on 
agents where deoxyribonucleic acid (DNA) is the initial primary target, i.e. "direct-acting 
genotoxins" like methylmethane sulfonate. However, it is well known that chemicals 
induce genotoxicity by interaction with a number of cellular targets in addition to DNA 
crosslinking. Indirect effects through inhibition of cellular enzymes, like ribonucleotide 
reductase and topoisomerase, as well as inhibition of critical macromolecules like 
tubulin can result in genotoxicity (Hurley, 2002). 
In addition to identification of novel pathways involved in cellular response to 
DNA damage, a number of studies have now demonstrated distinct responses in gene 
expression changes in cells exposed to different DNA damaging agents, suggesting 
the possibility of identifying fingerprints for different types of DNA damaging agents 
(Chang et al., 2002; Park et al., 2002; Heinloth et al., 2003). Studies of individual 
genes have demonstrated that transcript levels can change as a result of biomaterial 
contact (Lafrenie et al., 1998; Breen et al., 1999, Cukierman et al., 2001; Lam et al., 
2001).  
Huang et al. (2003) used the primary human gingival fibroblasts to examine the 
effect of six dentin bonding agents on the expression of c-fos and c-jun proto-
oncogene to evaluate the genotoxicity/mutagenicity and carcinogenicity potential of the 
dentin bonding agents. An important requirement for biomaterials agent is biological 
compatibility and they also should not induce an inflammatory or immune response. 
Numerous investigators of PHB have focused on the chemistry on bonding strength or 
on their effects on microleakage. However, there is very limited information available 
on biocompatibility tests, especially genotoxicity/mutagenicity and carcinogenicity of 
PHB agents. 
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1.7 Objectives 
1.7.1 General objectives 
The purpose of this study was to determine the genotoxicity of 
polyhydroxybutyrate (PHB) (produced in short solid fibre form  and manufactured by 
School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia).  
1.7.2 Specific objectives 
1. To determine the mutagenic effect of PHB on Salmonella strains using the 
Salmonella mutagenicity test (Ames test). 
2. To determine the cytotoxic and mutagenic effects of PHB on the chromosomes of 
human osteoblast cell line. 
3. To determine whether PHB altered the expression of proto-oncogenes (p53 and c-
myc) and anti-apoptotic genes (bcl-xl and bcl-xs) in the human fibroblast cell line. 
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CHAPTER TWO 
LITERATURE SURVEY 
 
2.1 Background 
In the past, there was no targeted development of biomaterials based on scientific 
criteria. Instead, devices consisting of materials that had been designed, synthesized 
and fabricated for various industrial needs (for example, the textile, aerospace and 
defense industries) were tested in a trial-and-error fashion in the bodies of animals and 
humans. These unplanned and sporadic attempts had (at best) modest success. Most 
frequently, the results were unpredictable, mixed and confounded both in success and 
in failure (Cooke et al., 1996). 
Because of the continuous and ever-expanding practical needs of medicine and 
health care practice, there are currently thousands of medical devices, diagnostic 
products and disposables in the market.  In fact, the range of applications continues to 
grow. To date, tens of millions of people have received medical implants. Undoubtedly, 
biomaterials have had a major impact on the practice of contemporary medicine and 
patient care in both saving and improving the quality of lives of humans and animals. 
Modern biomaterial practice still takes advantage of developments in the traditional, 
non medical materials field but is also (actually, more so than ever) aware of and 
concerned about the biocompatibility and biofunctionality of implants (Peppas and 
Langer, 1994). 
There is a necessity for replacing bone substance which has been lost due to 
traumatic or non-traumatic events. The lost bone can be replaced by endogenous or 
exogenous bone tissues, which is connected with several problems. The use of 
endogenous bone substance involves additional surgery (Parsons, 1988); moreover, 
the endogenous bone is available only in limited quantities (Willmann, 1993). The 
major disadvantage of exogenous bone implants is that they may be rejected by the 
human body and disease may be transmitted together with the implant (Willmann, 
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1993). Also, the clinical performance of exogenous bone is considerably inferior to 
fresh endogenous graft material (Parsons, 1988). For these reasons, there is a 
growing need for fabrication of artificial hard tissue replacement implants. 
Autogenous bone graft has been considered the gold standard for bone 
repairing procedures as it contains triggering ingredients necessary for bone formation 
in bone defect. However, the availability of the autograft bone is limited and the 
harvesting of autografts bone causes morbidity at the donor site. Bone defects 
resulting from congenital defects, inflammatory or tumorous destructive processes, 
trauma or bone gaps arising from osteotomy procedures are conventionally repaired 
using bone grafts. At present, the optimal grafting material is autologous bone, which 
provides the essential features of a graft material such as mechanical strength and 
living osteoblasts (Mulliken and Glowacki, 1980). Therefore, allografts are used as an 
alternative to autografts. Eventually, alternative bone substitute materials or 
biomaterials have been developed (Tuominen et al., 2000). 
The use of synthetic biocompatible, bioresorbable materials is increasing in 
orthopedic, plastic and dental surgery. Such materials are typically needed to augment 
autologous bone grafts or to fill bone voids or augment bone loss (e.g. bone loss 
caused by periodontal disease, bone defect or cavity due to trauma, cancer, disease or 
surgery and spinal fusion). The quality of a bone graft substitute is determined by its 
osteoconductive, osteoinductive and osteogenic properties (Bucholz, 2002). 
2.2     Biomaterials  
2.2.1   Definitions 
Biomaterial is a term used to indicate materials that constitute parts of medical 
implants, extracorporeal devices and disposables that have been utilized in medicine, 
surgery, dentistry and veterinary medicine as well as in every aspect of patient health 
care. The National Institutes of Health Consensus Development Conference defined 
biomaterial as ‘‘any substance (other than a drug) or combination of substances, 
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synthetic or natural in origin, which can be used for any period of time, as a whole or 
as a part of a system which treats, augments or replaces any tissue, organ or function 
of the body (Boretos and Eden, 1984). The common denominator in all the definitions 
that have been proposed for ‘‘biomaterials’’ is the undisputed recognition that 
biomaterials are distinct from other classes of materials because of the special 
biocompatibility criteria they must meet. 
2.2.2 Classifications 
Synthetic materials currently used for biomedical applications include metals, 
alloys, polymers and ceramics. Because the structures of these materials differ, they 
have different properties and, therefore, different uses in the body. When a synthetic 
material is placed within the human body, tissue reacts towards the implant in a variety 
of ways depending on the material type. The mechanism of tissue interaction depends 
on the tissue response to the implant surface. In general, there are three terms in 
which a biomaterial may be described into representing the tissues responses. These 
are bioinert, bioresorbable and bioactive (Heness and Ben-Nissan, 2004). 
2.2.2(a) Bioinert biomaterials 
The term bioinert refers to any material that once placed in the human body has 
minimal interaction with its surrounding tissue; examples of these are stainless steel, 
titanium, alumina, partially stabilised zirconia and ultra high molecular weight 
polyethylene. Generally, a fibrous capsule might form around bioinert implants and 
hence its biofunctionality relies on tissue integration through the implant. 
2.2.2(b) Bioresorbable biomaterials 
Bioresorbable refers to a material that upon placement within the human body 
starts to dissolve (resorbed) and slowly replaced by advancing tissue (such as bone). 
Common examples of bioresorbable materials are tricalcium phosphate [Ca3(PO4)2] 
and polylacticpolyglycolic acid copolymers. Calcium oxide, calcium carbonate and 
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gypsum are other common materials that have been utilised during the last three 
decades. 
2.2.2(c) Bioactive biomaterials 
 Bioactive refers to a material, which upon being placed within the human body 
interacts with the surrounding bone and in some cases, even soft tissue. This occurs 
through a time dependent kinetic modification of the surface, triggered by their implant-
ation within the living bone. An ion - exchange reaction between the bioactive implant 
and surrounding body fluids - results in the formation of a biologically active carbonate 
apatite (CHAp) layer on the implant that is chemically and crystallography-ically 
equivalent to the mineral phase in bone. Prime examples of these materials are 
synthetic hydroxyapatite [Ca10(PO4)6(OH)2], glass ceramic and bioglass (Park and 
Bronzino, 2003).  
2.2.3 Biological and synthetic biomaterials 
2.2.3(a) Biological biomaterials 
They are materials that are naturally produced. It is subdivided into autografts, 
allografts and xenografts. Autografts are grafts from the same organism, allografts from 
same species and xenografts are those made with grafts from other species.  
2.2.3(b) Synthetic biomaterials 
They are materials that are produced synthetically. It can be subdivided into 
metals, ceramic and glass and polymers. 
Metallic biomaterials have been used almost exclusively for load-bearing 
implants, such as hip and knee prostheses and fracture fixation wires, pins, screws 
and plates. Metals have also been used as parts of artificial heart valves, as vascular 
stents and as pacemaker leads. Although pure metals are sometimes used, alloys 
(metals containing two or more elements) frequently provide improvement in material 
properties, such as strength and corrosion resistance. Three material groups dominate 
biomedical metals: stainless steel, cobalt-chromium-molybdenum alloy and pure 
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titanium and titanium alloys. The main considerations in selecting metals and alloys for 
biomedical applications are biocompatibility, appropriate mechanical properties, 
corrosion resistance and reasonable cost (Ratner, 1993).  
Ceramics and glasses biomaterials are used as components of hip implants, 
dental implants, middle ear implants and heart valves. However, these biomaterials 
have been used less extensively than either metals or polymers. Some examples of 
ceramics that have been used for biomedical applications are alumina (Al2O3), zirconia 
(ZrO2), pyrolytic carbon, bioglass, hydroxyapatite [Ca10(PO4)6(OH)2] and tricalcium 
phosphate [Ca3(PO4)2] (Cooke et al., 1996).  
Polymeric biomaterials are the most widely used materials in biomedical 
applications. They are the materials of choice for cardiovascular devices as well as for 
replacement and augmentation of various soft tissues. Polymers are also used in drug 
delivery systems, in diagnostic aids and as a scalding material for tissue engineering 
applications. Examples of current applications include vascular grafts, heart valves, 
artificial hearts, breast implants, contact lenses, intraocular lenses, components of 
extracorporeal oxygenators, dialyzers and plasmapheresis units, coatings for 
pharmaceutical tablets and capsules, sutures, adhesives and blood substitutes (Peter 
et al., 1997). Examples of polymers are polyethylene, polyvinylchloride, polyester, 
PHB, silicone rubber, polyethyleneterephthalate, polytetrafluoroethylene, polymethyl-
methacrylate, polylactidecoglycolide, polylactic acid, polyglycolic acid and polylactide- 
co-lycolide. 
2.2.4 Applications of biomaterials 
2.2.4(a) Orthopaedic applications 
Metallic, ceramic and polymeric biomaterials are used in orthopedic 
applications. Metallic materials are normally used for load bearing members such as 
pins and plates and femoral stems. Ceramics such as alumina and zirconia are used 
for wear applications in joint replacements, while hydroxyapatite is used for bone 
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bonding applications to assist implant integration. Polymers such as ultra high mole-
cular weight polyethylene are used as articulating surfaces against ceramic 
components in joints (Cordingley et al., 2003). 
2.2.4(b) Dental applications 
Metallic biomaterials have been used as pins for anchoring tooth implants and 
as parts of orthodontic devices. Ceramics have found uses as tooth implants including 
alumina and dental porcelains. Hydroxyapatite has been used for coatings on metallic 
pins and to fill large bone voids resulting from disease or trauma (Thamaraiselvi and 
Rajeswari, 2004). 
2.2.4(c) Cardiovascular applications   
Many different biomaterials are used in cardiovascular applications depending 
on the specific application and the design. For instance, carbon in heart valves and 
polyurethanes for pacemaker leads. (Czernuszka, 1996). 
 2.2.4(d) Cosmetic surgery  
Materials such as silicones have been used in cosmetic surgery for applications 
such as breast augmentation.  
2.2.4(e) Others 
Although biomaterials are primarily used for medical applications, they are also 
used to grow cells in culture, to assay for blood proteins in the clinical laboratory, in 
processing biomolecules in biotechnology, for fertility regulation implants in cattle, in 
diagnostic gene arrays, in the aquaculture of oysters and for investigational cell-silicon 
"biochips" (Williams et al., 1999). The commonality of these applications is the 
interaction between biological systems and synthetic or modified natural materials. 
2.2.5 Biomaterials Act 
In August of 1998, USA Congress passed the Biomaterials Access Assurance 
Act to insulate biomaterials suppliers from liability in civil actions when their raw 
materials or component parts are used in implanted medical devices 
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(www.devicelink.com). An existing federal statute is designed to shield biomaterials 
suppliers from potential lawsuits. A recent case suggests that implant manufacturers 
can also assert the statute to protect their suppliers. Harm is defined as any injury to or 
damage suffered by an individual (Melissa and Julia, 2004) by any illness, disease or 
death resulting from that injury or damage and any loss to that individual or any other 
individual, resulting from that injury or damage. This definition of harm would appear to 
cover all damages and types of injury that could conceivably be alleged under any tort 
theory, including strict product liability. In short, the act insulates biomaterials suppliers 
for any type of injury to an individual in any court on the basis of any legal theory with 
regard to the suppliers' products used in implanted medical devices (Ishihara, 2000). 
2.3 Plastics  
Plastics have versatile qualities of strength, lightness, durability and resistance 
to degradation. They have become an important commodity to enhance the comfort 
and quality of life. Plastics are an essential part of almost all industries and have 
replaced glass and paper in packaging, but these very desirable properties have now 
become their greatest problem. Accumulation of recalcitrant plastics in the environment 
has become a world-wide problem. Solutions to plastic waste management include 
source reduction, incineration, recycling and bio- or photo-degradation. However, most 
of these have problems associated with them. Incineration of plastics is potentially 
dangerous and can be expensive. During the combustion of plastic waste, hydrogen 
cyanide can be formed from acrylonitrile-based plastics and may cause potential health 
hazards. Recycling can be done but is very tedious. The sorting of the wide variety of 
discarded plastic material is also a very time-consuming process. Moreover, the 
presence of a wide variety of additives such as pigments, coatings, fillers, limits the 
use of the recycled material. In such a scenario, biodegradable plastics offer the best 
solution to the environmental hazard posed by conventional plastics (Brandl et al., 
1990). 
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2.3.1 Biodegradable plastics  
2.3.1(a) Chemically synthesized polymers 
  Which include polyglycollic acid, polylactic acid, polycaprolactone, polyvinyl 
alcohol and polyethylene oxide. These materials are susceptible to enzymic or 
microbial attack. Since there is little information about the properties of these plastics 
therefore, they are not commercially available as substitute for plastics (Bonthrone et 
al., 1992).  
2.3.1(b) Starch-based biodegradable plastics 
 The starch is added as filler and cross-linking agent to produce a blend of 
starch and plastic (starch-polyethylene). Soil micro-organisms degrade the starch 
easily, thus breaking down the polymer matrix. These properties are significant in 
reduction of degradation time but such plastics are only partially degradable. The 
fragments left after starch removal are recalcitrant and remain in the environment for a 
long time (Shilpi and Ashok, 2005). 
2.3.1(c) Polyhydroxyalkanoates 
 Polyhydroxyalkanoates (PHAs) are the only 100% biodegradable polymers. 
They are polyesters of various hydroxyalkanoates (HAs) which are synthesized by 
numerous microorganisms as energy reserve materials when an essential nutrient 
such as nitrogen or phosphorus is available only in limited concentrations in the 
presence of excess carbon source. PHAs possess properties similar to various 
synthetic thermoplastics like polypropylene. They are also completely degraded to 
water and carbon dioxide under aerobic conditions and to methane under anaerobic 
conditions by micro-organisms in soil, sea, lake water and sewage (Mergaert et al., 
1992). 
2.4 Polyhydroxybutyrate  
Polyhydroxybutyrate (PHB) was the first of the PHA discovered and is the most 
widely studied and also best characterized of the PHA. It is accumulated as a 
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membrane enclosed inclusion in many bacteria at up to 80% of the dry cell weight. It 
has mechanical properties very similar to conventional plastics like polypropylene or 
polyethylene and can be extruded, moulded, spun into fibres, made into films and used 
to make heteropolymers with other synthetic polymers (Holmes, 1988). In spite of its 
numerous advantages, PHB has yet not been able to replace conventional plastics on 
a large scale because of its high cost (Shilpi and Ashok, 2005). 
Bacterial PHB is a crystalline polyester of great technological interest, because 
it is a truly biodegradable and highly biocompatible polymer (Doi et al., 1990). PHB is 
an aliphatic polyester synthesised by wide variety of microorganisms as an intracellular 
store of carbon and an ion sink (Dawes, 1986). 
PHB, first characterized in Alcaligenes eutrophus, is a biodegradable polymer, 
which can be completely degraded by enzymatic activities in the soil (Poirier et al., 
1992). PHB belongs to a class of polyesters of 3-hydroxy acids that are synthesized in 
various bacterial genera (Schubert et al., 1988; Hai et al., 2001).  
2.4.1 History of polyhydroxybutyrate  
        The presence of sudanophilic, lipid-like inclusions material was observed by 
Meyer, 1903 (cited by Sudesh et al., 2000) which were soluble in chloroform (Stapp, 
1924) was initially observed in Azotobacter chroococcum bacterium early last century. 
The chemical composition of similar inclusions in Bacillus megaterium bacterium was 
identified as poly(3-hydroxybutyric acid) P(3HB) by Lemoigne (1926) and Lemoigne 
(1927). By the end of the 1950s, enough evidence was already accumulated from 
studies on the genus Bacillus to suggest that P(3HB) functions as an intracellular 
reserve for carbon and energy in these bacteria (Williamson and Wilkinson, 1958; 
Doudoroff and Stanier, 1959). In fact, it was also demonstrated that the occurrence of 
this reserve polymer is a widespread phenomenon in gram-negative bacteria (Forsyth 
et al., 1958). In a review on the role and regulation of energy reserve polymers in 
microorganisms published in 1973 by Dawes and Senior, PHB received its first 
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extensive coverage as a bacterial storage material analogous to starch and glycogen. 
However, the 3-hydroxybutyric (3HB) unit wa, thought to be the only hydroxyalkanoate 
(HA) constituent that forms the building block for this microbial reserve polymer. 
In 1974, Wallen and Rohwedder reported the identification of 
hydroxyalkanoates other than 3HB. Among the HA units that were noted in chloroform 
extracts of activated sewage sludge, 3-hydroxyvalerate (3HV) and 3-hydroxyhexanoate 
(3HHX) were the major and the minor constituents, respectively. About a decade later, 
following the identification of the heteropolymers, the analyses of marine sediments by 
capillary gas chromatography revealed the presence of 3HB and 3HV as the 
predominant components among 11 other HA units (Findlay and White, 1983).  In the 
same report, it was also shown that batch-grown Bacillus megaterium cells 
accumulated a polymer which consisted of 95% 3HB, 3% 3-hydroxyheptanoate 
(3HHP), 2% of an 8-carbon HA and trace amounts of three other HA compounds. At 
around the same time, an interesting finding was made by Witholt and coworkers when 
they cultivated Pseudomonas oleovorans on n-octane (De Smet et al., 1983). 
Elemental analyses of the storage polymers thus accumulated by this bacterium 
showed that it consisted of principally 3-hydroxyoctanoate (3HO) units (De Smet et al., 
1983) and small amounts of 3HHX units (Lageveen et al., 1988). 
The identification of HA units other than 3HB in microbial PHA proved to have 
major impact on the research and commercial interest for this bacterial reserve 
polymer. While the homopolymer of P(3HB) is a brittle material with limited 
applications, the incorporation of a second monomer unit into P(3HB) can significantly 
enhance its useful properties. This finding is therefore highlighted as a landmark which 
signifies the beginning of the second developmental stage of research on PHA. It was 
in this stage that the first industrial production of a copolymer consisting of 3HB and 
3HV took place despite the fact that the potential of P(3HB) as a biodegradable 
thermoplastic was realized much earlier and patents were originally filed in 1962. At 
this stage, the research trend was to identify and characterize all the various potential 
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HA units that could possibly be a constituent of this bacterial polyester. This ultimately 
resulted in the discovery of numerous HA constituents (Doi et al., 1990) including 4HA 
(Kunioka, 1988) and 5HA (Doi et al., 1987) by the end of the 1980s. By this time, it was 
already clear that these storage polymers are synthesized not only in gram-negative 
bacteria but also in a wide range of gram-positive bacteria, aerobic (cyanobacteria) 
and anaerobic (non-sulfur and sulfur purple bacteria) photosynthetic bacteria, as well 
as in some archaebacteria (Anderson and Dawes, 1990; Steinbuchel, 1991).  
However, an astounding number of approximately 125 different HAs are known 
to occur (Rehm and Steinbuchel, 1999) and therefore a more general name comprising 
all these constituents, i.e. polyhydroxyalkanoates, has been used to designate this 
family of bacterial reserve polymers. 
Detailed studies on the bacterium Ralstonia eutropha (formerly known as 
Alcaligenes eutrophus) had revealed that only three enzymes are involved in the 
biosynthesis of P(3HB) from acetyl-CoA and that the regulation of P(3HB) synthesis in 
this bacterium is achieved at the enzyme level. The enzyme which carries out the 
polymerization reaction was identified as the key enzyme and it was designated as 
PHA synthase. To date, about 38 PHA synthase structural genes from more than 32 
different bacteria have been cloned. Highly conserved amino acids have been 
identified based on alignment analysis of the primary structures of these genes and 
also by site-specific mutagenesis studies (Gerngross et al., 1994).  
2.4.2 Manufacture of PHB 
Manufacturing process of PHB begins with sunlight. Through photosynthesis, 
carbon dioxide from the atmosphere is converted to carbohydrates via sugar beets or 
sugar cane. These carbohydrates are the raw material for the manufacture of PHB. 
PHB can be produced from glucose as a raw material or agricultural wastes like, for 
instance, molasses, which is refined from the processing of sugar beets and lactose. 
The sugar splits up in the metabolism to C2 building blocks, which are converted, over 
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several steps, to C4 monomers. Finally, PHB is polymerized (Kessler and Witholt, 
2001). 
Biosynthesis pathway of PHB has been studied in detail in Ralstonia eutropha 
(Schubert et al., 1988; Slater et al., 1988: Peoples and Sinskey, 1989). In this 
bacterium, the biosynthesis is initiated by the condensation of two acetyl-CoA 
molecules to acetoacetyl-CoA catalyzed by the enzyme β -ketothiolase. The gene for 
this enzyme is designated phbA. Acetoacetyl-CoA is then reduced to (R)-3-hydroxy-
butyryl-CoA by the NADPH-dependent acetoacetyl-CoA reductase; the gene was 
designated phbB. These enzymes have been found and studied in several PHB-
accumulating bacteria (Rehm and Steinbuchel, 1999).  
Advances in the biochemistry and molecular biology of PHA biosynthesis have 
resulted in the cloning of PHA biosynthesis genes from various bacteria (Steinbuchel, 
1991; Rehm and Steinbuchel, 1999). This has allowed for the development of 
recombinant bacteria which can produce PHA under the direction of heterologous 
genes (Lee, 1997). The biosynthetic pathway of PHB is shown in Figure 2.1 as 
described by Reddy et al. (2003). P (3HB) is synthesized by the successive action of b-
ketoacyl-CoA thiolase (phbA), acetoacetyl-CoA reductase (phbB) and PHB polymerase 
(phbC) in a three step pathway. The genes of the phbCAB operon encode the three 
enzymes. The promoter upstream of phbC transcribes the complete operon (phbCAB). 
2.4.3 PHB fermentation  
2.4.3(a) Pre-fermentation  
Selected bacteria are used and the cells are grown at 30°C in a stream of air in 
a mineral medium with glucose as a carbon-source. The cells multiply after 24 hours 
and reach approximately a cell density of 20 g/l. This is called pre-fermentation (Kim et 
al., 1994). 
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2.4.3(b) Fermentation 
  The cells continue to multiply and after 40-80 hours, reach a cell density of 100 
g/l. PHB occurs as discrete granules with diameters of 0.3 -1 µm in cells as storage 
material. At the end of the fermentation process, the cell has a dry mass 80 % in the 
form of PHB. For 1 kg of PHB, approximately 2.8 kg of sugar are needed (Yamane, 
1993). 
Fig 2.1 Biosynthetic pathway of poly (3-hydroxybutyrate) 
 
 
2.4.4 Physical properties of PHB 
The molecular weight of PHB produced from wild-type bacteria is usually in the 
range of 1x104 – 3x106 g/mol with a polydispersity of around two (Doi et al., 1990). The 
glass transition temperature of PHB is around 4°C while the melting temperature is 
near 180°C, as measured by calorimetric analysis (Kobayashi et al., 2000). The 
densities of crystalline and amorphous PHB are 1.26 and 1.18 g/cm3 respectively. The 
extension to break (5%) for PHB is however, markedly lower than that of polypropylene 
(400%). Therefore, PHB appears as a stiffer and more brittle plastic material  
compared to polypropylene (Sudesh et al., 2000).   
 phbC phbA phbB 
β - ketothiolase Acetoacetyl CoA Reductase PHB Polymerase 
Acetyl CoA Acetoacetyl   
CoA 
Poly 3-OH butyryl 
CoA 
Promoter 
Poly 3-OH butyrate 
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The recombinant E. coli harboring PHA biosynthesis gene from R. eutropha 
can produce ultra-high molecular weight PHB homopolymer. The weight-average 
molecular weight values were found to be in the range of 3x106 - 1.1x107 under special 
fermentation conditions. The chemical structure of PHB is   - {O- CH (CH3) – CH2 –(C 
= O)} n – (Kusaka et al., 1998).   
PHB is a fully biodegradable polyester with optical activity, piezoelectricity and 
very good barrier properties. PHB is a thermoplastic, belonging to the family of PHAs. 
It has physical and mechanical properties comparable to those of isotactic 
polypropylene. PHB is stiff and brittle. The degree of brittleness depends on the degree 
of crystallinity, glass temperature and microstructure (Song et al., 2001). At room 
temperature, the longer it is stored the more brittle it becomes. PHB does not contain 
any residues of catalysts like other synthetic polymers. It is not water-soluble but is 
100% biodegradable. PHB has low permeability for O2, H2O and CO2 but PHB has the 
disadvantage of high cost and is thermally unstable during processing, therefore the 
viscosity and molar mass decrease (Valentin and Dennis, 1997). 
2.4.5 Applications of PHB  
2.4.5(a) Applications in medicine  
 PHB is compatible with the blood and tissues of mammals. The monomer of 
PHB is a normal metabolic in the human blood. As the body reabsorbs PHB, it might 
be used as a surgical implant, in surgery, as seam threads for the healing of wounds 
and blood vessels. 
2.4.5(b) Applications in pharmacology  
 PHB can be used as microcapsules in therapy or as materials for cell and 
tablet packaging. 
2.4.5(c) Applications in industry  
In packaging for deep drawing articles in the food industry, for example, bottles, 
laminated foils, fishnets, potted flower, hygiene, fast food, one-way cups, agricultural 
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foils and fibres in textile. PHB was found more interesting applications as an implant 
material due to its biocompatibility and resorbability (Miller and Williams, 1987; Boeree 
et al., 1993). PHB appeared ideal for use as temporary stents, bone plates, patches, 
nails and screws (Malm et al., 1992; Peng et al., 1996). In some cases, its brittle 
mechanical properties limit its use. 
2.5 Problem description 
Nowadays, plastics and synthetic polymers are mainly produced from petro- 
chemical elements, which do not decompose, thus resulting in environmental pollution. 
During combustion, water and carbon dioxide are released into the atmosphere, i.e. an 
increase in the carbon dioxide concentration in the atmosphere occurs. By recycling 
polymers, the material quality decreases. Biological polymers are part of a cycle, i.e. 
water and carbon dioxide are used during the photosynthesis in the plant. The bacteria 
used carbohydrates by fermentation in the manufacture of PHB. In the USA, Europe 
and Japan it is expected that biodegradable materials will be important due to their 
material properties being suitable for a wide range of fields. Waste is currently causing 
serious environmental problems in many countries, especially in industrialized 
countries. In household waste, 30% are all types of packaging foil, i.e. packaging foils 
for foods, bags and coated foil on paper. Making eco-friendly products such as 
bioplastics is one such reality that can help us overcome the problem of pollution 
caused by non-degradable plastics (Reddy et al., 2003). 
2.6 Biomaterials and cancer 
Since breast implants first came on the market in 1962, between 1.5 and 2 
million women in the United States have had breast augmentation surgery. About 80% 
of the surgeries were for cosmetic reasons while 20% were for breast reconstruction 
following breast cancer surgery (Brinton et al., 2001). 
The Food and Drug Administration (FDA) banned the use of silicone implants 
for breast enlargements in 1992 because there was little information on their long-term 
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safety. The FDA now only permits silicone implants to be used in controlled clinical 
trials of women seeking breast reconstruction (www.cancer.gov). 
Baird and Rea (1999) reported 14 patients with temporomandibular joint (TMJ) 
who had alloplastic implants and exhibited chronic signs and symptoms of chemical 
sensitivity. These patients were well before their implantation whereas they had 
memory loss, confusion, imbalance, dizziness, non-immune vasculitis, petechiae, 
spontaneous bruising, edema, Raynaud's phenomenon, pain and autoimmune 
dysfunction after implantation. Laboratory data also showed immunological 
abnormalities, including positive autoantibodies and altered T and B lymphocyte 
function and provocation skin testing showed reaction to their implant material. The 
symptoms of patients with jaw implants were similar to those patients who experience 
complications from their breast implants (Baird and Rea, 1999). 
2.7 Biocompatibility testing       
Any medical device that comes into direct or indirect contact with a patient must 
be tested for biocompatibility. Even if a device does not physically touch the patients, in 
some cases it may release chemical constituents that could be harmful. The degree of 
concern about a material depends on its composition, the nature and duration of its 
contact with the patients. Biocompatibility is the ability of a material to perform with an 
appropriate host response in a specific application (Williams, 1999). 
Recognition of an implant material as biocompatible nowadays depends on a 
large number of factors such as absence of cytotoxicity, mutagenicity, carcinogenicity, 
exclusion of allergenic properties, physical, chemical and biological “inertia” and 
stability in its biological environment. Therefore, before new materials are approved for 
medical use, mutagenesis system to exclude cytotoxic, mutagenic or carcinogenic 
properties is applied world wide. There are more than one hundred different testing 
methods for collecting evidence of carcinogenic and mutagenic activity. Many of them 
are based on the principle that genotoxicity or mutagenicity serves as an indicator for 
